Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
LEXX
Lexaria Bioscience
$0.88
Login to see Lexaria Bioscience (LEXX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Trading below its fair value
Chart
$1 (-12.00%)
$0.84 (+4.76%)
$1.05 (-16.19%)
$2.76 (-68.12%)
LEXX has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Price under $5
High volatilty
LEXX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Trading below its fair value
LEXX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
LEXX Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayLEXX Earnings
The TTM reflects 12-month period, providing review of LEXX financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
NVO
59.63
+1.52%
LLY
839.87
+2.44%
PFE
27.37
+1.07%
MRK
89.19
-0.36%
What is LEXX current stock price?
What are LEXX stock strengths?
What risks are associated with LEXX stock?
When is LEXX next earnings report?
What is LEXX market cap and volume?
What is LEXX's current Stock IQ?
Should I buy LEXX stock right now?
Is LEXX a Strong Buy right now?
What does a 'Strong Buy' rating mean for LEXX?
What does a 'Strong Sell' rating mean for LEXX?
What factors influence LEXX's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
LEXX
Lexaria Bioscience
Current Price
$0.88
Stock Insights
Strengths
Trading below its fair value
Linked to LEXX
NVO
59.63
+1.52%
LLY
839.87
+2.44%
PFE
27.37
+1.07%
MRK
89.19
-0.36%
Login to unlock Lexaria Bioscience (LEXX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$1 (-12.00%)
$0.84 (+4.76%)
$1.05 (-16.19%)
$2.76 (-68.12%)
LEXX Analysts Opinion
LEXX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Trading below its fair value
LEXX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
LEXX Street view is extremely bullish and have positive views on the near-term outlook
LEXX has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Price under $5
High volatilty
Average key support and resistance price levels.
Login to displayLEXX Earnings
The TTM data reflects the most recent 12-month period, providing overview of LEXX financial performance.
LEXX Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
LEXX Latest Analysis
LEXX: Biodistribution Study Results . By As we step into fall Lexaria Bioscience Corporation (NASDAQ:LEXX) continues to work on multiple GLP-1 trials. Most notably it reported the last patient-last visit for the Phase Ib study designated GLP-1-H24-4 and reported data from its rodent biodistribution study. It also closed a $4.0 million capital raise earlier this week. Activity in the obesity and GLP-1 agonist space has been robust in 2025 with a number of deals and new trial data announced. In th
Thu Oct 2, 2025
Lexaria Bioscience announces ~$4M registered direct offering of shares.
Fri Sep 26, 2025
Why Are Lexaria Bioscience Shares Soaring 45% After Hours?. ) experienced a dramatic 45.10% surge in after-hours trading on Thursday climbing to $2.22 from its closing price of $1.53. According to data the biotech company’.s regular trading session had already shown strength with a 7.75% gain.Check out the current price of .Lexaria’.s after-hours surge came after the company filed with the
Fri Sep 26, 2025
Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading.
Fri Sep 26, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
LEXX Stock trends
LEXX Stock performance
LEXX Stock analysis
LEXX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings